Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?

× No keyword cloud information.

8 in total

Review 1. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors: Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal: Curr Pharm Biotechnol Date: 2012-07 Impact factor: 2.837

2. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

Authors: Sonia Tusell Wennier; Jia Liu; Shoudong Li; Masmudur M Rahman; Mahmoud Mona; Grant McFadden
Journal: Mol Ther Date: 2012-01-10 Impact factor: 11.454

Review 3. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.

Authors: Xiu-Wei Zhang; Yu-Xiang Ma; Yang Sun; Yu-Bo Cao; Qin Li; Chong-An Xu
Journal: Target Oncol Date: 2017-06 Impact factor: 4.493

4. Considerations for the prediction of survival time in pancreatic cancer based on registry data.

Authors: Gaurav Bajaj; Erin Dombrowsky; Qilu Yu; Banke Agarwal; Jeffrey S Barrett
Journal: J Pharmacokinet Pharmacodyn Date: 2013-07-12 Impact factor: 2.745

5. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.

Authors: Christian Dittrich; Robert Königsberg; Martina Mittlböck; Klaus Geissler; Azra Sahmanovic-Hrgovcic; Johannes Pleiner-Duxneuner; Martin Czejka; Philipp Buchner
Journal: Invest New Drugs Date: 2018-07-12 Impact factor: 3.850

Review 6. Advanced pancreatic carcinoma: current treatment and future challenges.

Authors: Anastasios Stathis; Malcolm J Moore
Journal: Nat Rev Clin Oncol Date: 2010-01-26 Impact factor: 66.675

7. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.

Authors: Mei-Ying Liao; Jun-Kai Lai; Mark Yen-Ping Kuo; Ruei-Min Lu; Cheng-Wei Lin; Ping-Chang Cheng; Kang-Hao Liang; Han-Chung Wu
Journal: Oncotarget Date: 2015-09-22

8. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.

Authors: Shadi Mamaghani; Satish Patel; David W Hedley
Journal: BMC Cancer Date: 2009-04-30 Impact factor: 4.430

8 in total